MeSH Review:
Acromegaly
- Growth hormone treatment induces mammary gland hyperplasia in aging primates. Ng, S.T., Zhou, J., Adesanya, O.O., Wang, J., LeRoith, D., Bondy, C.A. Nat. Med. (1997)
- Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome. Luboshitzky, R., Barzilai, D. JAMA (1980)
- Growth hormone-releasing peptides and their analogs. Camanni, F., Ghigo, E., Arvat, E. Frontiers in neuroendocrinology. (1998)
- Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. Zapf, J., Walter, H., Froesch, E.R. J. Clin. Invest. (1981)
- Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Grunstein, R.R., Ho, K.K., Sullivan, C.E. Ann. Intern. Med. (1994)
- Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. Landolt, A.M., Schmid, J., Wimpfheimer, C., Karlsson, E.R., Boerlin, V. N. Engl. J. Med. (1989)
- Evidence of an endogenous digitalis-like factor in the plasma of patients with acromegaly. Deray, G., Rieu, M., Devynck, M.A., Pernollet, M.G., Chanson, P., Luton, J.P., Meyer, P. N. Engl. J. Med. (1987)
- No effect of bromocriptine in acromegaly: a controlled trial. Lindholm, J., Riishede, J., Vestergaard, S., Hummer, L., Faber, O., Hagen, C. N. Engl. J. Med. (1981)
- Evaluation of acromegaly by radioimmunoassay of somatomedin-C. Clemmons, D.R., Van Wyk, J.J., Ridgway, E.C., Kliman, B., Kjellberg, R.N., Underwood, L.E. N. Engl. J. Med. (1979)
- Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Kopchick, J.J., Parkinson, C., Stevens, E.C., Trainer, P.J. Endocr. Rev. (2002)
- Insulin action in human adipose tissue in acromegaly. Bolinder, J., Ostman, J., Werner, S., Arner, P. J. Clin. Invest. (1986)
- Primary structures of three human pancreas peptides with growth hormone-releasing activity. Esch, F.S., Böhlen, P., Ling, N.C., Brazeau, P.E., Wehrenberg, W.B., Guillemin, R. J. Biol. Chem. (1983)
- Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Veysey, M.J., Thomas, L.A., Mallet, A.I., Jenkins, P.J., Besser, G.M., Wass, J.A., Murphy, G.M., Dowling, R.H. Gut (1999)
- Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Clemmons, D.R., Underwood, L.E., Ridgway, E.C., Kliman, B., Kjellberg, R.N., Van Wyk, J.J. Am. J. Med. (1980)
- Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Caron, P., Morange-Ramos, I., Cogne, M., Jaquet, P. J. Clin. Endocrinol. Metab. (1997)
- Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. Freda, P.U., Shen, W., Heymsfield, S.B., Reyes-Vidal, C.M., Geer, E.B., Bruce, J.N., Gallagher, D. J. Clin. Endocrinol. Metab. (2008)
- Bone mineral density and parameters of bone metabolism in patients with acromegaly. Kotzmann, H., Bernecker, P., Hübsch, P., Pietschmann, P., Woloszczuk, W., Svoboda, T., Geyer, G., Luger, A. J. Bone Miner. Res. (1993)
- IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. O'Connell, T., Clemmons, D.R. J. Clin. Endocrinol. Metab. (2002)
- Blood pressure response to an angiotensin II antagonist in patients with acromegaly. Ogihara, T., Hata, T., Maruyama, A., Mikami, H., Nakamaru, M., Okada, Y., Kumahara, Y. J. Clin. Endocrinol. Metab. (1979)
- Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Jaquet, P., Saveanu, A., Gunz, G., Fina, F., Zamora, A.J., Grino, M., Culler, M.D., Moreau, J.P., Enjalbert, A., Ouafik, L.H. J. Clin. Endocrinol. Metab. (2000)
- Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B., Kuhn, J.M. J. Clin. Endocrinol. Metab. (1993)
- Growth hormone-releasing factor stimulates pancreatic enzyme secretion. Pandol, S.J., Seifert, H., Thomas, M.W., Rivier, J., Vale, W. Science (1984)
- Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels. Miyakawa, M., Saji, M., Tsushima, T., Wakai, K., Shizume, K. J. Clin. Endocrinol. Metab. (1988)
- Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Pack, S.D., Kirschner, L.S., Pak, E., Zhuang, Z., Carney, J.A., Stratakis, C.A. J. Clin. Endocrinol. Metab. (2000)
- Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. Simsolo, R.B., Ezzat, S., Ong, J.M., Saghizadeh, M., Kern, P.A. J. Clin. Endocrinol. Metab. (1995)
- Muscle sympathetic nerve activity in patients with acromegaly. Capaldo, B., Lembo, G., Rendina, V., Guida, R., Marzullo, P., Colao, A., Lombardi, G., Saccà, L. J. Clin. Endocrinol. Metab. (2000)
- Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Murray, R.D., Kim, K., Ren, S.G., Chelly, M., Umehara, Y., Melmed, S. J. Clin. Invest. (2004)
- NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Gorden, P., Comi, R.J., Maton, P.N., Go, V.L. Ann. Intern. Med. (1989)
- Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings. Bassetti, M., Arosio, M., Spada, A., Brina, M., Bazzoni, N., Faglia, G., Giannattasio, G. J. Clin. Endocrinol. Metab. (1988)
- Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. Moller, D.E., Moses, A.C., Jones, K., Thorner, M.O., Vance, M.L. J. Clin. Endocrinol. Metab. (1989)
- Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. Arosio, M., Garrone, S., Bruzzi, P., Faglia, G., Minuto, F., Barreca, A. J. Clin. Endocrinol. Metab. (2001)
- Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. Lamberts, S.W., Uitterlinden, P., Verschoor, L., van Dongen, K.J., del Pozo, E. N. Engl. J. Med. (1985)
- Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Williams, G., Ball, J.A., Burrin, J.M., Joplin, G.F., Bloom, S.R. Lancet (1986)
- Bromocriptine reduces growth hormone in acromegaly. Bell, P.M., Atkinson, A.B., Hadden, D.R., Kennedy, L., Leslie, H., Merrett, J.D., Sheridan, B. Arch. Intern. Med. (1986)
- Acromegaly. Bloom, S.R. Am. J. Med. (1987)